Etienne Sokal

About Etienne Sokal

Etienne Sokal, With an exceptional h-index of 86 and a recent h-index of 45 (since 2020), a distinguished researcher at Université Catholique de Louvain, specializes in the field of Pediatric liver diseases, Stem cells, Regenerative medicine, Inborn errors of metabolism.

His recent articles reflect a diverse array of research interests and contributions to the field:

Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study

Characterization of immune cell populations in the microenvironment of mice liver during the progression of chronic liver diseases to hepatocellular carcinoma

Long-Term Maintenance of Response and Improved Liver Health With Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC): 2-Year Data From the MARCH …

Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with Primary Biliary Cholangitis-an ELTR study

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings

Immune regulation and therapeutic application of T regulatory cells in liver diseases

Etienne Sokal Information

University

Position

Institut de Recherche Expérimentale et Clinique (IREC) Cliniques

Citations(all)

26717

Citations(since 2020)

8775

Cited By

22889

hIndex(all)

86

hIndex(since 2020)

45

i10Index(all)

348

i10Index(since 2020)

202

Email

University Profile Page

Google Scholar

Etienne Sokal Skills & Research Interests

Pediatric liver diseases

Stem cells

Regenerative medicine

Inborn errors of metabolism

Top articles of Etienne Sokal

Characterization of immune cell populations in the microenvironment of mice liver during the progression of chronic liver diseases to hepatocellular carcinoma

2024

Etienne Sokal
Etienne Sokal

H-Index: 46

Mustapha Najimi
Mustapha Najimi

H-Index: 29

Long-Term Maintenance of Response and Improved Liver Health With Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC): 2-Year Data From the MARCH …

Journal of Hepatology

2023/6/1

Type of calcineurin inhibitor and long-term outcomes following liver transplantation in patients with Primary Biliary Cholangitis-an ELTR study

JHEP Reports

2024/4/25

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial

The Lancet Gastroenterology & Hepatology

2024/4/23

Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection

Journal of Pediatric Gastroenterology and Nutrition

2024/4/21

ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource‐limited settings

Journal of Pediatric Gastroenterology and Nutrition

2024/2/18

Etienne Sokal
Etienne Sokal

H-Index: 46

Immune regulation and therapeutic application of T regulatory cells in liver diseases

2024/3/20

Umbilical Cord Mesenchymal Stromal/Stem Cells and Their Interplay with Th-17 Cell Response Pathway

Cells

2024/1/16

SURGICAL BILIARY DIVERSION IS ASSOCIATED WITH AN INCREASED RISK OF LIVER TRANSPLANTATION OR DEATH IN ALAGILLE SYNDROME

Hepatology

2023

Etienne Sokal
Etienne Sokal

H-Index: 46

Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (MARCH-PFIC): a randomized placebo-controlled phase 3 study

2023

Etienne Sokal
Etienne Sokal

H-Index: 46

Hepatocellular carcinoma cell lines growth inhibition by liver-derived mesenchymal stem cells in direct 3D co-culture

2023

Mustapha Najimi
Mustapha Najimi

H-Index: 29

Etienne Sokal
Etienne Sokal

H-Index: 46

OC7 Maralixibat-treated patients with Alagille syndrome demonstrate event-free survival in a natural history comparison with patients with from the GALA database: application …

2023/7/1

ANALYSIS OF LONG-TERM SAFETY IN MARALIXIBAT-TREATED PARTICIPANTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM MARCH-ON

2023

Etienne Sokal
Etienne Sokal

H-Index: 46

Population pharmacokinetics and dosing simulation of the β-lactam temocillin in liver transplanted pediatric patients

2023

Senescence and senotherapies in biliary atresia and biliary cirrhosis

Aging (Albany NY)

2023/6/6

Alagille syndrome livers display premature senescence

Senescence and senotherapies in pediatric biliary cirrhosis

2023

CHARACTERISATION OF KUPFFER CELL AND INFILTRATING MONO-MACROPHAGE POPULATIONS IN CCl4 INDUCED LIVER DAMAGE model

2023

Etienne Sokal
Etienne Sokal

H-Index: 46

Mustapha Najimi
Mustapha Najimi

H-Index: 29

Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic …

Journal of Hepatology

2023/6/1

Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

Hepatology

2023/12/25

See List of Professors in Etienne Sokal University(Université Catholique de Louvain)

Co-Authors

academic-engine